-
"Technosphere Tech is extraordinary...Tyvaso market will Triple." -Wedbush PacGrow Health Conference
#PulmonaryArterialHypertension#PAH#Pulmonary#biotech#MedTech#Lungs$MNKD$UTHR https://ir.unither.com/events-presentations …pic.twitter.com/0rnzMdUz0I
-
A new study has identified a region in the genome that could contribute to increased susceptibility to suffering
#PulmonaryArterialHypertension among carriers of a mutation in the gene BMPR2, which is responsible for the heritable form of the disease http://bit.ly/2PqdHYp pic.twitter.com/erLPlp946H
-
Straight from United Therapeutics 10-Q: Compares TreT & Substantial Lifestyle benefits compared to TYVASO (their own product).
$UTHR$MNKD#PulmonaryArterialHypertension#PAH#Lungs#BetterQualityOfLife#Health#Innovation#Technosphere https://ir.unither.com/node/25031/html pic.twitter.com/JR1oUCjiMV
-
CEO Martine Rothblatt (from today's
$UTHR earnings call):$MNKD#PulmonaryArterialHypertension#PAH#Lungs#BetterQualityOfLife#Health#Innovation#Technosphere#Biotech#BREEZEpic.twitter.com/RuwqPjy28j
-
Recruiting has begun for the BREEZE study
$UTHR$MNKD#PulmonaryArterialHypertension#PAH#Lungs#BetterQualityOfLife#Health#Innovation#Technosphere#Biotech#BREEZE https://clinicaltrials.gov/ct2/show/NCT03950739 …pic.twitter.com/3veCYYySRM
-
Features and Outcomes of Methamphetamine-associated
#PulmonaryArterialHypertension, by@docroham et al. http://ow.ly/ejFS30iYr7h@atscommunitypic.twitter.com/Mm1F37LBRv
-
#papworthauthors new publication: Familial pulmonary arterial hypertension by KDR heterozygous loss of function. https://buff.ly/2RS3IOd .#PAH#pulmonaryArterialHypertension#KDRgenepic.twitter.com/w25ZXfd4AA
-
@AcceleronPharma announces sotatercept achieved primary and secondary endpoints in the PULSAR trial http://bit.ly/36Qq5b5#VascularNews#pulmonaryarterialhypertension -
#Acceleron Announces#PositiveData from#PULSAR Phase 2 Trial of#Sotatercept in Patients with#PulmonaryArterialHypertension https://www.trialsitenews.com/acceleron-announces-positive-data-from-pulsar-phase-2-trial-of-sotatercept-in-patients-with-pulmonary-arterial-hypertension/ …#clinicaltrials#healthcare -
Reliability and responsiveness of incremental shuttle walk test to estimate exercise capacity in patients with pulmonary arterial hypertension R. Ishrat, A. Mujaddadi, M.S. Ali, D. Talwar, M.E. Hussain https://doi.org/10.3920/CEP190056 …
#CEPinPress#pulmonaryarterialhypertension -
This
@AcceleronPharma drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in#pulmonaryarterialhypertension, some now see blockbuster potential.$XLRN shares shot up 50% Tues. https://xconomy.com/boston/2020/01/28/third-times-the-charm-as-acceleron-drug-shows-early-promise-in-pah/ …#PAH -
#papworthauthors new publication: Safety of riociguat for the treatment of pulmonary arterial hypertension: Final data cut from the expert registry. https://buff.ly/30ZJp4x .#pulmonaryArterialHypertension#PAH#riociguat -
Cardiologist Dr. Raymond Benza discusses
#PulmonaryArterialHypertension and$PHAS once weekly VIP analogue PB1046 currently in clinical trials for adults with#PAH. Listen to the@phaware podcast here.https://link.medium.com/EDXXBK4D21 -
Study suggests mechanical basis for using
#RightVentricle &#LeftVentricle end-diastolic volume ratio as clinical index for delineating disease severity, estimating RV free wall contractility in#PulmonaryArterialHypertension patients http://ow.ly/BAFM50xxq7F@simula_researchpic.twitter.com/xk28PuGfRl
-
Have you visited the
@MedTechStrat#CommunityBlog on http://MyStrategist.com ? Take a look at our archives for some great free content, such as this installation of#InMedTechHistory on#PulmonaryArterialHypertension: http://bit.ly/2DGzDcJ pic.twitter.com/txxWCyUwA5
-
Tomorrow the
#PAHPatientCharter will be available to everyone living with#PulmonaryArterialHypertension. Here’s a sneak peek from@PhDeutschland’s Daniela#PAH#WithYouUntilPHIsntpic.twitter.com/IKylE8vCwz -
Three days until we unveil the
#PAHPatientCharter. Here@wginsing , PH specialist nurse, tells us why the Charter is important#PAH#PulmonaryArterialHypertension#WithYouUntilPHIsntpic.twitter.com/2O0biAcNDF -
#ADAMTS8 promotes the development of#PulmonaryArterialHypertension and right ventricular failure. Learn more about ADAMTS8 as a possible novel therapeutic target in a study from@TohokuUniPR http://ow.ly/ZO0W30pPFHj pic.twitter.com/7fRC2BlI0y
-
mtROS-induced ca2+ entry via TRPV4 regulates mitochondrial morphology in lung microvascular endothelial cells. Read more here in AJP-Lung: https://buff.ly/2Utzdhl
@suresh_lab@Shimoda_Lab@damarlalab@HopkinsMedicine#PulmonaryArterialHypertension#PAH#Mitochondriapic.twitter.com/EZGOw1VjXV
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.